Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target- Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
Heidelberg Pharma AG and Chiome Bioscience Inc., Tokyo, Japan, today announced the signing of an exclusive, target-specific research and option agreement. Heidelberg Pharma Research GmbH signed this collaboration, which will combine one of Chiome’s monoclonal antibodies against one specific target with Heidelberg Pharma’s proprietary ATAC® platform.